All right, best stocks in the market from Josh Brown. The spotlight today is on Viva. Vev on the list since May 29th of 2025.Tell me why. >> This might be like the only time this stock has ever been mentioned on on the network. Nobody nobody talks about it, but it >> could be the last time.It's >> it's this incredible company, Scott, and it literally is demanding that we pay attention to it based on um its performance. So, the stock broke out in May. It has since been consolidating just below um those 52- w ...

Well, I got some breaking news out of the White House, which means we're going to go to Aean Jabvers. Aean, Brian, uh, Eli Liy is the company that is in negotiations with the White House for a pharma deal similar to the one uh that Fizer struck earlier today that confirmed by the White House to me just within the past couple of moments. You can see uh Lily shares there have been moving throughout the day.That's because the president mentioned the company in the Fizer event. He said how terrific Eli Liy has ...

The big winner of this deal clearly will be the American Pac. There is no doubt about it. They are the ones that will see significant impact in their ability to buy medicines.But I would argue that uh it is not the only winner. I think who else is a winner here. It is American innovation and American economy.In our industry, we had two major overhangs that have substantially reduced our valuations and create concerns for us in our ability to invest. We are addressing both of them right now and I will speak ...

The pharmaceutical industry’s US lobbying organization announced a new website on Monday to connect patients with companies selling discounted medicines online https://t.co/GH7Rr3W36L ...

Core Viewpoint - Vertex Pharmaceuticals is a significant player in the biotechnology sector, focusing on treatments for serious diseases, particularly cystic fibrosis (CF) therapies, which are crucial for revenue generation [1] Group 1: Stock Performance and Analyst Ratings - On September 26, 2025, Stephens initiated coverage on Vertex with an "Overweight" rating, indicating a positive outlook despite the stock being priced at $24.61 at that time [2][6] - Vertex's stock has dropped nearly 24% over the past six months due to challenges in its drug pipeline [2][6] - As of now, Vertex's stock is priced at $24.61, with a slight decrease of 1.20% today, and has experienced a trading range between $23.13 and $60.71 over the past year [5] Group 2: Challenges in Drug Pipeline - The decline in Vertex's stock is primarily attributed to trial failures in programs targeting acute pain, diabetes, and neuropathic pain [3][6] - A significant setback occurred in August 2025 when a phase II study on VX-993, a Nav1.8 inhibitor for acute pain, failed to show significant improvement, leading to the halting of its advancement as a monotherapy [3] Group 3: Sales and Growth Potential - Despite the challenges, Vertex's CF sales remain robust, driven by products like Trikafta and Alyftrek, particularly among younger patients [4][6] - New product launches such as Journavx and Casgevy are anticipated to enhance growth, although their market uptake is still in the early stages [4]

Five things to know ahead of today's opening bell. President Trump threatening the pharmaceutical industry with 100% tariffs unless drug companies manufacture or at least start to build manufacturing plants in the United States. The president also saying that he plans to slap a 25% tariff on imported heavy trucks starting October 1st.Separately, President Trump said yesterday he hopes to take some of the money raised by his tariffs and give it to US farmers. Retaliation to President Trump's tariffs have red ...

Drug Approval & Efficacy - Half (50%) of approved cancer drugs lack proof of extending survival for approved uses [1] - The pharmaceutical industry's primary motive is generating profits for shareholders [1] - Financial pressures can lead to rushed clinical trials and approvals based on uncertain evidence [2] Treatment & Dosage - Lower dosages can result in less revenue for pharmaceutical companies [2] - A second line of treatment may not always be beneficial for patients [2] Patient Needs & Conflicts - Clinicians and researchers should focus on patient needs, which can sometimes conflict with other factors [3]

Company Overview - Pfizer Inc. has entered into a definitive agreement to acquire Metsera, a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases [1][2] - The acquisition is expected to enhance Pfizer's portfolio with differentiated oral and injectable therapies that have potential best-in-class efficacy and safety profiles [1][2] Acquisition Details - Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion [3] - The agreement includes a contingent value right (CVR) that could provide additional payments of up to $22.50 per share based on specific clinical and regulatory milestones [3] Metsera's Portfolio - Metsera has four programs in clinical development, including MET-097i and MET-233i, both of which are injectable GLP-1 receptor agonists [2][4] - The company is also advancing oral GLP-1 RA candidates and additional preclinical hormone therapeutics aimed at addressing unmet needs in obesity treatment [2][4] Strategic Importance - The acquisition aligns with Pfizer's strategy to invest in impactful opportunities within the growing obesity treatment market, which is associated with over 200 health conditions [2] - Pfizer aims to leverage its manufacturing and commercial infrastructure to accelerate the development of Metsera's promising therapeutic candidates [2][5]

Roche Holding says it will acquire biopharmaceutical company 89bio in a deal valued at $3.5 billion, bolstering the Swiss pharmaceutical giant’s pipeline of cardiovascular, renal, and metabolic disease treatments https://t.co/9tmRggnAGn ...

Group 1 - Warner Bros. Discovery shares fell after being downgraded by TD Cowan due to concerns that potential gains from a sale to Paramount Skydance could be lost if the deal does not materialize [1][2][5] - The S&P 500 and Nasdaq experienced declines from record highs as the Federal Reserve's two-day meeting commenced, with Warner Bros. Discovery being the worst-performing stock in the S&P 500 [2][5] - Dave & Buster's Entertainment shares plunged after missing profit and sales estimates, with comparable store sales declining and warnings about inflation and tariffs affecting business [3][5] Group 2 - Novo Nordisk shares rose following positive results from a Phase 3 trial of a new weight-loss drug that operates differently from traditional GLP-1 inhibitors [4] - Steel Dynamics shares advanced after providing a better-than-expected outlook on performance across its units [5] - Rocket Lab shares declined as the company announced agreements to sell $750 million in stock to raise cash [3]